CSL's $1.15 Bn R&D program has developed orphan medicines with over 95% efficacy rate
Register to read the full analysis —or— Upgrade to access more features
#vaccines
#Research and Development
#medicine
#Innovative products
Actual Direct Impact
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.